Resistance of colorectal cancer cells to radiation and 5-FU is associated with MELK expression

Biochemical and Biophysical Research Communications

Volumn 412, Issue 2, 2011, Pages 207-213

  Choi, Seungho ^a   Ku, Ja Lok ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

Cancer stem cell; Chemoradiotherapy; Drug resistance; MELK; Radio resistance; Rectal cancer

Indexed keywords

FLUOROURACIL; LEUCINE ZIPPER PROTEIN; MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE; MESSENGER RNA; SMALL INTERFERING RNA; SNU 503; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CANCER RESISTANCE; CELL CYCLE; CELL PROLIFERATION; CELL STRAIN SNU 503; CHEMORADIOTHERAPY; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFECT; GAMMA RADIATION; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIVITY; RECTUM CANCER;

ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; GAMMA RAYS; GENE KNOCKDOWN TECHNIQUES; HUMANS; PROTEIN-SERINE-THREONINE KINASES; RADIATION TOLERANCE; RNA, SMALL INTERFERING;

EID: 80052022586     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.07.060     Document Type: Article

References (30)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
2. Meyer J.E., Narang T., Schnoll-Sussman F.H., Pochapin M.B., Christos P.J., Sherr D.L. Increasing incidence of rectal cancer in patients aged younger than 40years: an analysis of the surveillance, epidemiology, and end results database. Cancer 2010, 116:4354-4359.
3. Bosset J.F., Collette L., Calais G., Mineur L., Maingon P., Radosevic-Jelic L., Daban A., Bardet E., Beny A., Ollier J.C. Chemotherapy with preoperative radiotherapy in rectal cancer. N. Engl. J. Med. 2006, 355:1114-1123.
4. Gerard J.P., Conroy T., Bonnetain F., Bouche O., Chapet O., Closon-Dejardin M.T., Untereiner M., Leduc B., Francois E., Maurel J., Seitz J.F., Buecher B., Mackiewicz R., Ducreux M., Bedenne L. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J. Clin. Oncol. 2006, 24:4620-4625.
5. Krishnan S., Janjan N.A., Skibber J.M., Rodriguez-Bigas M.A., Wolff R.A., Das P., Delclos M.E., Chang G.J., Hoff P.M., Eng C., Brown T.D., Crane C.H., Feig B.W., Morris J., Vadhan-Raj S., Hamilton S.R., Lin E.H. Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer. Int. J. Radiat. Oncol. Biol. Phys. 2006, 66:762-771.
6. Longley D.B., Allen W.L., Johnston P.G. Drug resistance predictive markers and pharmacogenomics in colorectal cancer. Biochim. Biophys. Acta 2006, 1766:184-196.
7. Baumann M., Krause M., Hill R. Exploring the role of cancer stem cells in radioresistance. Nat. Rev. Cancer 2008, 8:545-554.
8. Frank N.Y., Schatton T., Frank M.H. The therapeutic promise of the cancer stem cell concept. J. Clin. Invest. 2010, 120:41-50.
9. Gottesman M.M., Fojo T., Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2002, 2:48-58.
10. Lizcano J.M., Goransson O., Toth R., Deak M., Morrice N.A., Boudeau J., Hawley S.A., Udd L., Makela T.P., Hardie D.G., Alessi D.R. LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. EMBO J. 2004, 23:833-843.
11. Davezac N., Baldin V., Blot J., Ducommun B., Tassan J.P. Human pEg3 kinase associates with and phosphorylates CDC25B phosphatase: a potential role for pEg3 in cell cycle regulation. Oncogene 2002, 21:7630-7641.
12. Lin M.L., Park J.H., Nishidate T., Nakamura Y., Katagiri T. Involvement of maternal embryonic leucine zipper kinase (MELK) in mammary carcinogenesis through interaction with Bcl-G, a pro-apoptotic member of the Bcl-2 family. Breast Cancer Res. 2007, 9:R17.
13. Nakano I., Paucar A.A., Bajpai R., Dougherty J.D., Zewail A., Kelly T.K., Kim K.J., Ou J., Groszer M., Imura T., Freije W.A., Nelson S.F., Sofroniew M.V., Wu H., Liu X., Terskikh A.V., Geschwind D.H., Kornblum H.I. Maternal embryonic leucine zipper kinase (MELK) regulates multipotent neural progenitor proliferation. J. Cell Biol. 2005, 170:413-427.
14. Gray D., Jubb A.M., Hogue D., Dowd P., Kljavin N., Yi S., Bai W., Frantz G., Zhang Z., Koeppen H., de Sauvage F.J., Davis D.P. Maternal embryonic leucine zipper kinase/murine protein serine-threonine kinase 38 is a promising therapeutic target for multiple cancers. Cancer Res. 2005, 65:9751-9761.
15. Guo B., Godzik A., Reed J.C. Bcl-G, a novel pro-apoptotic member of the Bcl-2 family. J. Biol. Chem. 2001, 276:2780-2785.
16. Nakano I., Masterman-Smith M., Saigusa K., Paucar A.A., Horvath S., Shoemaker L., Watanabe M., Negro A., Bajpai R., Howes A., Lelievre V., Waschek J.A., Lazareff J.A., Freije W.A., Liau L.M., Gilbertson R.J., Cloughesy T.F., Geschwind D.H., Nelson S.F., Mischel P.S., Terskikh A.V., Kornblum H.I. Maternal embryonic leucine zipper kinase is a key regulator of the proliferation of malignant brain tumors, including brain tumor stem cells. J. Neurosci. Res. 2008, 86:48-60.
17. Pickard M.R., Green A.R., Ellis I.O., Caldas C., Hedge V.L., Mourtada-Maarabouni M., Williams G.T. Dysregulated expression of Fau and MELK is associated with poor prognosis in breast cancer. Breast Cancer Res. 2009, 11:R60.
18. Jeon Y.K., Kim S.H., Choi S.H., Kim K.H., Yoo B.C., Ku J.L., Park J.G. Promoter hypermethylation and loss of CD133 gene expression in colorectal cancers. World J. Gastroenterol. 2010, 16:3153-3160.
19. Hemmati H.D., Nakano I., Lazareff J.A., Masterman-Smith M., Geschwind D.H., Bronner-Fraser M., Kornblum H.I. Cancerous stem cells can arise from pediatric brain tumors. Proc. Natl. Acad. Sci. USA 2003, 100:15178-15183.
20. Pasquinelli G., Vinci M.C., Gamberini C., Orrico C., Foroni L., Guarnieri C., Parenti A., Gargiulo M., Ledda F., Caldarera C.M., Muscari C. Architectural organization and functional features of early endothelial progenitor cells cultured in a hyaluronan-based polymer scaffold. Tissue Eng. A 2009, 15:2751-2762.
21. Thannickal V.J., Fanburg B.L. Reactive oxygen species in cell signaling. Am. J. Physiol. Lung Cell. Mol. Physiol. 2000, 279:L1005-L1028.
22. Guillem J.G., Chessin D.B., Cohen A.M., Shia J., Mazumdar M., Enker W., Paty P.B., Weiser M.R., Klimstra D., Saltz L., Minsky B.D., Wong W.D. Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer. Ann. Surg. 2005, 241:829-836. (discussion 836-838).
23. Sauer R., Becker H., Hohenberger W., Rodel C., Wittekind C., Fietkau R., Martus P., Tschmelitsch J., Hager E., Hess C.F., Karstens J.H., Liersch T., Schmidberger H., Raab R. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N. Engl. J. Med. 2004, 351:1731-1740.
24. Brugarolas J., Chandrasekaran C., Gordon J.I., Beach D., Jacks T., Hannon G.J. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 1995, 377:552-557.
25. Longley D.B., Harkin D.P., Johnston P.G. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer 2003, 3:330-338.
26. Li M.H., Ito D., Sanada M., Odani T., Hatori M., Iwase M., Nagumo M. Effect of 5-fluorouracil on G1 phase cell cycle regulation in oral cancer cell lines. Oral Oncol. 2004, 40:63-70.
27. Maybaum J., Ullman B., Mandel H.G., Day J.L., Sadee W. Regulation of RNA- and DNA-directed actions of 5-fluoropyrimidines in mouse T-lymphoma (S-49) cells. Cancer Res. 1980, 40:4209-4215.
28. Pawlik T.M., Keyomarsi K. Role of cell cycle in mediating sensitivity to radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2004, 59:928-942.
29. Badouel C., Chartrain I., Blot J., Tassan J.P. Maternal embryonic leucine zipper kinase is stabilized in mitosis by phosphorylation and is partially degraded upon mitotic exit. Exp. Cell Res. 2010, 316:2166-2173.
30. Badouel C., Korner R., Frank-Vaillant M., Couturier A., Nigg E.A., Tassan J.P. M-phase MELK activity is regulated by MPF and MAPK. Cell Cycle 2006, 5:883-889.